Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:07:28.011Z.
Calculation as of: 2026-10-06T15:07:28.011Z.
Quote observation: 2026-10-06T15:05:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 880fb47a961da82dee7b372bf013e19f9356fddf046c7e26e64914405e113cb3
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2023-12-11.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$258.73M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.43M
PS Ratio
N/A
TTM Avg
8336935.98
3Y Avg
3234328.97
5Y Avg
2173022.38
Market Cap
$266.79M
PS Ratio
95.66
TTM Avg
82.20
3Y Avg
35.74
5Y Avg
24.54
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $258.73M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | N/A | 0.95 | 38.57 | 83.32 |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.48M | 2.12 | 1.86 | 1.92 | 2.22 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | 8336935.98 | 3234328.97 | 2173022.38 |
| AC Immune S.A. (ACIU)vs › | $262.66M | 12.10 | 46.34 | 33239.72 | 23903.84 |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | 525.95 | 794.15 | 209.97 | 146.32 |
| OraSure Technologies, Inc. (OSUR)vs › | $264.72M | 2.35 | 1.95 | 1.47 | 1.49 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.79M | 95.66 | 82.20 | 35.74 | 24.54 |
| Invivyd, Inc. (IVVD)vs › | $247.23M | 4.24 | 5.57 | 10.86 | 10.86 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2023-12-11 | 478.26 |
| 2023-12-08 | 549.36 |
| 2023-12-07 | 616.20 |
| 2023-12-06 | 661.70 |
| 2023-12-05 | 755.08 |
| 2023-12-04 | 747.50 |
| 2023-12-01 | 727.59 |
| 2023-11-30 | 602.93 |
| 2023-11-29 | 592.50 |
| 2023-11-28 | 565.95 |
| 2023-11-27 | 521.40 |
| 2023-11-24 | 535.62 |
| 2023-11-22 | 516.66 |
| 2023-11-21 | 521.87 |
| 2023-11-20 | 537.51 |
| 2023-11-17 | 522.35 |
| 2023-11-16 | 525.66 |
| 2023-11-15 | 521.87 |
| 2023-11-14 | 500.07 |
| 2023-11-13 | 498.65 |
| 2023-11-10 | 510.97 |
| 2023-11-09 | 514.29 |
| 2023-11-08 | 504.33 |
| 2023-11-07 | 495.80 |
| 2023-11-06 | 497.70 |
| 2023-11-03 | 476.37 |
